nach oben

Annals of Hematology

Erschienen in:

01.06.2013 | Review Article

The evolving use of arsenic in pharmacotherapy of malignant disease

verfasst von: Athena Kritharis, Thomas P. Bradley, Daniel R. Budman

Erschienen in: Annals of Hematology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.

Antman KH (2001) Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6(Suppl 2):1–2PubMedCrossRef

Doyle D (2009) Notoriety to respectability: a short history of arsenic prior to its present day use in haematology. Br J Haematol 145(3):309–317PubMedCrossRef

Mari F, Bertol E, Fineschi V, Karch SB (2004) Channelling the Emperor: what really killed Napoleon? J R Soc Med 97(8):397–399. doi:10.1258/jrsm.97.8.397 PubMedCrossRef

Liu JLY, Wu Q et al (2008) Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther 326:363–368PubMedCrossRef

Miller M (1998) Scientists explore use of arsenic in therapy. J Natl Cancer Inst 90(24):1866–1867PubMed

Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl 2):3–10PubMedCrossRef

Dilda PJ, Hogg PJ (2007) Arsenical-based cancer drugs. Cancer Treat Rev 33(6):542–564. doi:10.1016/j.ctrv.2007.05.001 PubMedCrossRef

Breinl A, Todd JL (1907) Atoxyl in the Treatment of Trypanosomiasis. Br Med J 1(2403):132–134PubMedCrossRef

Thorburn AL (1983) Paul Ehrlich: pioneer of chemotherapy and cure by arsenic (1854–1915). Brit J Vener Dis 59(6):404–405

10.

Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315–3324PubMed

11.

Anonymous (2001) Arsenic-based therapy benefits leukemia patients. FDA Consum 35 (1):4

12.

Anonymous (2004) Arsenic trioxide: new preparation. (2004) Acute promyelocytic leukaemia: encouraging results but persistent doubts. Prescrire Int 13 (72):135–137

13.

Amadori S, Fenaux P, Ludwig H, O’Dwyer M, Sanz M (2005) Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 21(3):403–411. doi:10.1185/030079904X20349 PubMedCrossRef

14.

Anderson KC, Boise LH, Louie R, Waxman S (2002) Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 8(1):12–25PubMedCrossRef

15.

Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135(2):174–183. doi:10.1111/j.1365-2141.2006.06280.x PubMedCrossRef

16.

Bonati A, Rizzoli V, Lunghi P (2006) Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 7(6):397–405PubMedCrossRef

17.

Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR (2007) Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 138(4):467–478. doi:10.1111/j.1365-2141.2007.06675.x PubMedCrossRef

18.

Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G (2000) Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 85(9):1002–1003PubMed

19.

Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R (2004) Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 125(4):470–476. doi:10.1111/j.1365-2141.2004.04941.x PubMedCrossRef

20.

Sekeres MA (2007) New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Clin Lymphoma Myelom 8(Suppl 1):S7–S12CrossRef

21.

Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, Yao YT, Chou WC, Chung CY, Wang CH, Shen MC, Chen YC (1998) Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 103(4):1092–1095PubMedCrossRef

22.

Kwong YL, Todd D (1997) Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 89(9):3487–3488PubMed

23.

Moore DF, O’Callaghan CA, Berlyne G, Ogg CS, Davies HA, House IM, Henry JA (1994) Acute arsenic poisoning: absence of polyneuropathy after treatment with 2,3-dimercaptopropanesulphonate (DMPS). J Neurol Neurosurg Psychiatry 57(9):1133–1135PubMedCrossRef

24.

Ratnaike RN (2003) Acute and chronic arsenic toxicity. Postgrad Med J 79(933):391–396PubMedCrossRef

25.

Sankpal UT, Goodison S, Abdelrahim M, Basha R (2011) Targeting sp1 transcription factors in prostate cancer therapy. Med Chem 7(5):518–525PubMedCrossRef

26.

Das NK, Sengupta SR (2008) Arsenicosis: diagnosis and treatment. Indian J Dermatol Venereol Leprol 74(6):571–581PubMedCrossRef

27.

Sengupta SR, Das NK, Datta PK (2008) Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 74(6):559–570PubMedCrossRef

28.

Caldwell KL, Jones RL, Verdon CP, Jarrett JM, Caudill SP, Osterloh JD (2009) Levels of urinary total and speciated arsenic in the US population: National Health and Nutrition Examination Survey 2003–2004. J Expo Sci Environ Epidemiolo 19(1):59–68. doi:10.1038/jes.2008.32 CrossRef

29.

Ablain J, de The H (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117(22):5795–5802. doi:10.1182/blood-2011-02-329367 PubMedCrossRef

30.

Agostinelli E, Seiler N (2006) Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids 31(3):341–355. doi:10.1007/s00726-005-0271-8 PubMedCrossRef

31.

Liu Y, Zhang W, Zhang X, Qi Y, Huang D, Zhang Y (2011) Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway. Exp Biol Med 236(5):592–597. doi:10.1258/ebm.2011.010276 CrossRef

32.

Liu Q, Zhang H, Smeester L, Zou F, Kesic M, Jaspers I, Pi J, Fry RC (2010) The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3:37. doi:10.1186/1755-8794-3-37 PubMedCrossRef

33.

Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, Fu Q, Qian JQ, Xiang JZ (2006) Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin 27(8):1078–1084. doi:10.1111/j.1745-7254.2006.00345.x PubMedCrossRef

34.

Jang M, Kim Y, Won H, Lim S, K.R J, Dashdorj A, Min YH, Kim S-Y, Shokat KM, Ha J, Kim SS (2012) Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide, vol 72. First published. doi:10.1158/0008-5472.can-12-1110

35.

Binet F, Girard D (2008) Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2. J Leukoc Biol 84(6):1613–1622. doi:10.1189/jlb.0708421 PubMedCrossRef

36.

Huang HS, Liu ZM, Cheng YL (2011) Involvement of glycogen synthase kinase-3beta in arsenic trioxide-induced p21 expression. Toxicol Sci 121(1):101–109. doi:10.1093/toxsci/kfr023 PubMedCrossRef

37.

Stepnik M, Ferlinska M, Smok-Pieniazek A, Gradecka-Meesters D, Arkusz J, Stanczyk M (2011) Assessment of the involvement of oxidative stress and mitogen-activated protein kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines. Med Oncol. doi:10.1007/s12032-011-9920-1

38.

Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia: As₂O₃ induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88(3):1052–1061PubMed

39.

Catalano A, Dawson MA, Somana K, Opat S, Schwarer A, Campbell LJ, Iland H (2007) The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 110(12):4073–4076. doi:10.1182/blood-2007-06-095554 PubMedCrossRef

40.

Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ (2000) Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14(2):262–270PubMedCrossRef

41.

Meng R, Zhou J, Sui M, Li Z, Feng G, Yang B (2010) Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line. Science China Life Sciences 53(1):87–93. doi:10.1007/s11427-010-0004-9 PubMedCrossRef

42.

Lu D, Bai XC, Gui L, Li M, Zheng WS, Han XQ, Luo SQ (2003) Arsenic trioxide-induced apoptosis of human malignant lymphoma cell lines and its mechanisms. Di Yi Jun Yi Da Xue Xue Bao 23(10):997–1001PubMed

43.

Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, Sun X (2006) Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 97(7):675–681. doi:10.1111/j.1349-7006.2006.00230.x PubMedCrossRef

44.

Liu ZM, Huang HS (2008) Arsenic trioxide phosphorylates c-Fos to transactivate p21(WAF1/CIP1) expression. Toxicol Appl Pharmacol 233(2):297–307. doi:10.1016/j.taap.2008.08.015 PubMedCrossRef

45.

Mann KK, Colombo M, Miller WH Jr (2008) Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol Cancer Ther 7(6):1680–1687. doi:10.1158/1535-7163.MCT-07-2164 PubMedCrossRef

46.

Liu Y, Hock JM, Sullivan C, Fang G, Cox AJ, Davis KT, Davis BH, Li X (2010) Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem 111(6):1546–1555. doi:10.1002/jcb.22886 PubMedCrossRef

47.

Barginear MF, Leung M, Budman DR (2009) The hedgehog pathway as a therapeutic target for treatment of breast cancer. Breast Cancer Res Treat 116(2):239–246. doi:10.1007/s10549-009-0423-0 PubMedCrossRef

48.

Kim J, Lee JJ, Gardner D, Beachy PA (2010) Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. PNAS 107(30):13432–13437. doi:10.1073/pnas.1006822107 PubMedCrossRef

49.

Patlolla AK, Tchounwou PB (2005) Cytogenetic evaluation of arsenic trioxide toxicity in Sprague–Dawley rats. Mutat Res 587(1–2):126–133. doi:10.1016/j.mrgentox.2005.08.007 PubMed

50.

Soriano C, Creus A, Marcos R (2008) Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay. Mutat Res 646(1–2):1–7. doi:10.1016/j.mrfmmm.2008.08.014 PubMed

51.

Soriano C, Creus A, Marcos R (2007) Gene-mutation induction by arsenic compounds in the mouse lymphoma assay. Mutat Res 634(1–2):40–50. doi:10.1016/j.mrgentox.2007.05.014 PubMed

52.

Aballay LR, Diaz MD, Francisca FM, Munoz SE (2011) Cancer incidence and pattern of arsenic concentration in drinking water wells in Cordoba, Argentina. Int J Environ Health Res. doi:10.1080/09603123.2011.628792

53.

Tokar EJ, Qu W, Waalkes MP (2011) Arsenic, stem cells, and the developmental basis of adult cancer. J Toxicol Sci 120(Suppl 1):S192–S203. doi:10.1093/toxsci/kfq342

54.

Le XC, Lu X, Ma M, Cullen WR, Aposhian HV, Zheng B (2000) Speciation of key arsenic metabolic intermediates in human urine. Anal Chem 72(21):5172–5177PubMedCrossRef

55.

Carney DA (2008) Arsenic trioxide mechanisms of action—looking beyond acute promyelocytic leukemia. Leuk Lymphoma 49(10):1846–1851PubMedCrossRef

56.

Cui X, Kobayashi Y, Akashi M, Okayasu R (2008) Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer. Curr Med Chem 15(22):2293–2304PubMedCrossRef

57.

Ghosh P, Banerjee M, Giri AK, Ray K (2008) Toxicogenomics of arsenic: classical ideas and recent advances. Mutat Res 659(3):293–301PubMedCrossRef

58.

Hernandez A, Marcos R (2008) Genetic variations associated with interindividual sensitivity in the response to arsenic exposure. Pharmacogenomics 9(8):1113–1132PubMedCrossRef

59.

Tseng CH (2007) Metabolism of inorganic arsenic and non-cancerous health hazards associated with chronic exposure in humans. J Environ Biol 28(2 Suppl):349–357PubMed

60.

Tseng CH (2007) Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25(1):1–22PubMedCrossRef

61.

Vahter M, Akesson A, Liden C, Ceccatelli S, Berglund M (2007) Gender differences in the disposition and toxicity of metals. Environ Res 104(1):85–95PubMedCrossRef

62.

Ghosh P, Banerjee M, Giri AK, Ray K (2008) Toxicogenomics of arsenic: classical ideas and recent advances. Mutat Res 659(3):293–301PubMedCrossRef

63.

Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, Devesa V, Styblo M (2007) Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med 232(1):3–13

64.

Charoensuk V, Gati WP, Weinfeld M, Le XC (2009) Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol Appl Pharmacol 239(1):64–70. doi:10.1016/j.taap.2009.05.016 PubMedCrossRef

65.

Drobna Z, Walton FS, Harmon AW, Thomas DJ, Styblo M (2010) Interspecies differences in metabolism of arsenic by cultured primary hepatocytes. Toxicol Appl Pharmacol 245(1):47–56. doi:10.1016/j.taap.2010.01.015 PubMedCrossRef

66.

Styblo M, Del Razo LM, LeCluyse EL, Hamilton GA, Wang C, Cullen WR, Thomas DJ (1999) Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol 12(7):560–565. doi:10.1021/tx990050l PubMedCrossRef

67.

Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A (2004) The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 198(3):458–467PubMedCrossRef

68.

Waters SB, Devesa V, Fricke MW, Creed JT, Styblo M, Thomas DJ (2004) Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem Res Toxicol 17(12):1621–1629. doi:10.1021/tx0497853 PubMedCrossRef

69.

70.

Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176(2):127–144PubMedCrossRef

71.

Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES, Del Razo LM (2005) Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113(3):250–254PubMedCrossRef

72.

Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176(2):127–144PubMedCrossRef

73.

Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD (2006) Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol 36(2):99–133PubMedCrossRef

74.

Raml R, Rumpler A, Goessler W, Vahter M, Li L, Ochi T, Francesconi KA (2007) Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh. Toxicol Appl Pharmacol 222(3):374–380PubMedCrossRef

75.

Wang Z, Zhou J, Lu X, Gong Z, Le XC (2004) Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 17(1):95–103PubMedCrossRef

76.

Lin CJ, Wu MH, Hsueh YM, Sun SS, Cheng AL (2005) Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective. Cancer Chemother Pharmacol 55(2):170–178PubMedCrossRef

77.

Hernandez-Zavala A, Matousek T, Drobna Z, Paul DS, Walton F, Adair BM, Jiri D, Thomas DJ, Styblo M (2008) Speciation analysis of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J Anal At Spectrom 23:342–351PubMedCrossRef

78.

Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P (2008) Analytical artefacts in the speciation of arsenic in clinical samples. Anal Chim Acta 607(1):83–91PubMedCrossRef

79.

Schlawicke Engstrom K, Nermell B, Concha G, Stromberg U, Vahter M, Broberg K (2009) Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat Res 667:4–14

80.

Hernandez A, Xamena N, Surralles J, Sekaran C, Tokunaga H, Quinteros D, Creus A, Marcos R (2008) Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat Res 637(1–2):80–92PubMed

81.

Fujihara J, Fujii Y, Agusa T, Kunito T, Yasuda T, Moritani T, Takeshita H (2009) Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol Appl Pharmacol 234(1):41–46PubMedCrossRef

82.

De Chaudhuri S, Ghosh P, Sarma N, Majumdar P, Sau TJ, Basu S, Roychoudhury S, Ray K, Giri AK (2008) Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes. Environ Health Perspect 116(4):501–505PubMed

83.

Calderon RL, Hudgens E, Le XC, Schreinemachers D, Thomas DJ (1999) Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 107(8):663–667PubMedCrossRef

84.

Ghaffari SH, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A (2006) Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol 17(10):1553–1559. doi:10.1093/annonc/mdl150 PubMedCrossRef

85.

Lo-Coco F, Ammatuna E (2006) The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematology Am Soc Hematol Educ Program 156–161:514. doi:10.1182/asheducation-2006.1.156

86.

Bachleitner-Hofmann T, Kees M, Gisslinger H (2002) Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk Lymphoma 43(8):1535–1540. doi:10.1080/1042819021000002857 PubMedCrossRef

87.

Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15(5):735–741PubMedCrossRef

88.

Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29(20):2753–2757. doi:10.1200/JCO.2010.32.2107 PubMedCrossRef

89.

Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116(19):3751–3757. doi:10.1182/blood-2010-02-269621 PubMedCrossRef

90.

Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504–510. doi:10.1200/JCO.2008.18.6130 PubMedCrossRef

91.

Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owoeye I, Dauses T, Schachter-Tokarz E, Gallagher RE (2010) Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28(6):1047–1053. doi:10.1200/JCO.2009.25.5158 PubMedCrossRef

92.

Lo-Coco F AG, Orlando SM, Ferrara F, Vignetti M, Paola Fazi, Eros Di Bona, Giorgina S (2012) ATRA and arsenic trioxide (ATO) versus atra and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. In: 54th ASH Annual Meeting and Exposition, Atlanta, GA

93.

Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci 106(9):3342–3347. doi:10.1073/pnas.0813280106 PubMedCrossRef

94.

Mathews BG V, Lakshmi KM et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627–2632CrossRef

95.

Lu D-P, Qiu J-Y, Jiang B, Wang Q, Liu K-Y, Liu Y-R, Chen S-S (2002) Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report, vol 99. doi:10.1182/blood.V99.9.3136

96.

Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW, Kwong YL (2003) Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 102(1):407–408. doi:10.1182/blood-2003-01-0298 PubMedCrossRef

97.

Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL (2011) Oral arsenic trioxide based maintenance regimens for first complete remission of acute promyelocytic leukemia: a ten-year follow-up study. Blood. doi:10.1182/blood-2011-05-354530

98.

Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E (2002) Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73(1):61–73PubMedCrossRef

99.

Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS, Schipper HM, Miller WH Jr (2005) Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 105(3):1237–1245. doi:10.1182/blood-2004-05-1772 PubMedCrossRef

100.

Diaz Z, Laurenzana A, Mann KK, Bismar TA, Schipper HM, Miller WH Jr (2007) Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia 21(10):2117–2127. doi:10.1038/sj.leu.2404891 PubMedCrossRef

101.

Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP (2011) Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12(10)

102.

Zhang W, Wang L, Fan Q, Wu X, Wang F, Wang R, Ma Z, Yang J, Lu SH (2011) Arsenic trioxide re-sensitizes ER alpha-negative breast cancer cells to endocrine therapy by restoring ER alpha expression in vitro and in vivo. Oncol Rep 26(3):621–628. doi:10.3892/or.2011.1352 PubMed

103.

Alsina M (2003) Multiple myeloma: increasing our treatment options. Cancer Control 10(5):357–358PubMed

104.

Berenson JR, Yellin O (2008) New drugs in multiple myeloma. Curr Opin Support Palliat Care 2(3):204–210. doi:10.1097/SPC.0b013e3283090475 PubMedCrossRef

105.

Chanan-Khan AA, Borrello I, Lee KP, Reece DE (2010) Development of target-specific treatments in multiple myeloma. Br J Haematol 151(1):3–15. doi:10.1111/j.1365-2141.2010.08262.x PubMedCrossRef

106.

Gan F, Cao B, Wu D, Chen Z, Hou T, Mao X (2011) Exploring old drugs for the treatment of hematological malignancies. Curr Med Chem 18(10):1509–1514PubMedCrossRef

107.

Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG (2007) Novel therapies in myeloma. Curr Opin Hematol 14(6):609–615. doi:10.1097/MOH.0b013e3282f0e948 PubMedCrossRef

108.

Sanaat Z, Rezazadeh M, Vaez Gharamaleki J, Eivazi Ziae J, Esfahani A (2011) Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. Acta Med Iran 49(8):504–508PubMed

109.

Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, Preti HA, Kamble RT, Zu Y, Ballon DJ, Chang CC (2010) Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 34(1):85–92. doi:10.1016/j.leukres.2009.05.024 PubMedCrossRef

110.

Munshi NCDR, Zangari M (1999) Marked anti-tumor effect of arsenic trioxide (As2O3) in high risk refractory multiple myeloma. Blood 94:123a

111.

Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF (2006) Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24(16):2456–2464. doi:10.1200/JCO.2005.03.7903 PubMedCrossRef

112.

Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, Holler C, Stocher M, Prokesch A, Papak C, Scheideler M, Trajanoski Z, Greil R (2008) Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 86(5):541–552. doi:10.1007/s00109-008-0314-6 PubMedCrossRef

113.

Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H (2011) Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 117(21):4831–4868. doi:10.1002/cncr.26097 CrossRef

114.

Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, Pahlman S (2009) Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther 8(1):160–170. doi:10.1158/1535-7163.MCT-08-0595 PubMedCrossRef

115.

Li N, Song Y, Zhou J, Fang B (2012) Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia. J Hem and Oncol 5(61). doi:1069344–990823

116.

Lin Q, Song Y, Fang B (2012) Arsenic trioxide for refractory aplastc anemia. Ann Hematol. doi:10.1007/s00277-012-1605-0

117.

Sigmon C, Patch S (2010) A pilot survey of in-service home arsenic tracked in from chromated copper arsenate-treated decks. J Environ Health 72(6):18–22

118.

Sengupta SR, Das NK, Datta PK (2008) Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 74(6):559–570PubMedCrossRef

119.

Lin CC, Pu YS, Hsu CH, Keng HY, Cheng AL, Yang CH (2008) Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. Urol Oncol 26(6):659–661PubMedCrossRef

120.

Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM (2005) Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol 206(3):299–308PubMedCrossRef

121.

Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133(11):881–885PubMedCrossRef

122.

Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S (2001) Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97(5):1514–1516PubMedCrossRef

123.

Raffoux ERP, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21(12):2326–2334PubMedCrossRef

124.

Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114(25):5126–5135. doi:10.1182/blood-2009-07-216457 PubMedCrossRef

125.

Navas-Acien ASE, Pastor-Barriuso R et al (2008) Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 200:814–822CrossRef

126.

Coronado-Gonzalez JA, Del Razo LM, Garcia-Vargas G, Sanmiguel-Salazar F, Escobedo-de la Pena J (2007) Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res 104(3):383–389PubMedCrossRef

127.

Yen CC, Lu FJ, Huang CF, Chen WK, Liu SH, Lin-Shiau SY (2007) The diabetogenic effects of the combination of humic acid and arsenic: in vitro and in vivo studies. Toxicol Lett 172(3):91–105PubMedCrossRef

128.

Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E (2006) Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect 114(5):641–648PubMedCrossRef

129.

Diaz-Villasenor A, Burns AL, Hiriart M, Cebrian ME, Ostrosky-Wegman P (2007) Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol 225(2):123–133PubMedCrossRef

130.

Kritharis A BT, Budman DR (2011) Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL). Proc ASCO Abstract no. e19724

131.

Tapio S, Grosche B (2006) Arsenic in the aetiology of cancer. Mutat Res 612(3):215–246PubMedCrossRef

132.

Agency USEP (1999) Integrated Risk Information System (IRIS) on Arsenic. National Center for Environmental Assessment, Office of Research and Development

133.

Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45(11 Pt 2):5895–5899PubMed

134.

Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, Liaw J, Smith AH (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99(12):920–928. doi:10.1093/jnci/djm004 PubMedCrossRef

135.

Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, Kligerman AD (2001) Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 14(4):355–361PubMedCrossRef

136.

Kitchin KT (2001) Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172(3):249–261. doi:10.1006/taap.2001.9157 PubMedCrossRef

137.

Cuzick J, Evans S, Gillman M, Price Evans DA (1982) Medicinal arsenic and internal malignancies. Br J Cancer 45(6):904–911PubMedCrossRef

138.

Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 28(24):3866–3871. doi:10.1200/JCO.2010.28.5031 PubMedCrossRef

Titel: The evolving use of arsenic in pharmacotherapy of malignant disease
verfasst von: Athena Kritharis
Thomas P. Bradley
Daniel R. Budman
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 6/2013
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-013-1707-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East

Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis

Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial

Autoimmune hemolytic anemia with warm-reactive immunoglobulin M antibody in multicentric Castleman disease